• 中国科技论文统计源期刊(中国科技核心期刊)
  • 中国医药卫生核心期刊
  • 中国抗癌协会系列期刊
YANG Hui-fang, WANG Qun. Efficacy and Safety of Ustekinumab for Plaque Psoriasis: A Meta-Analysis[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 157-162. DOI: 10.3969/j.issn.1671-5144.2012.03.018
Citation: YANG Hui-fang, WANG Qun. Efficacy and Safety of Ustekinumab for Plaque Psoriasis: A Meta-Analysis[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 157-162. DOI: 10.3969/j.issn.1671-5144.2012.03.018

Efficacy and Safety of Ustekinumab for Plaque Psoriasis: A Meta-Analysis

More Information
  • Received Date: April 12, 2012
  • Published Date: June 27, 2012
  • Objective To assess the efficacy and safety of Ustekinumab for plaque psoriasis with meta-analysis. Method Both foreign and Chinese databases were searched to identity randomized controlled trials(RCTs) that reported the efficacy and safety of Ustekinumab for plaque psoriasis. We also searched the references of all primary studies. Two reviewers assessed the quality of each trial and extracted data independently. The Cochrane Collaboration’s RevMan 4.2.2 software was used for statistical analysis. Results A total of 4 RCTs were included, including 2 437 patients. Meta-analysis results suggested that Ustekinumab was superior to placebo for moderate to severe plaque psoriasis at week 12,but there was no significant difference between the two groups of Ustekinumab at week 12(RR=0.94,95%CI 0.82~1.07, P=0.34); at week 28, the Ustekinumab 90 mg group was superior to the Ustekinumab 45 mg group in the skin lesions subsidence(RR=0.89, 95%CI 0.84~0.95, P=0.000 6), but there was no significant difference in the improvement of the life quality(RR=0.93, 95%CI 0.85~1.01, P=0.08). The most common adverse events were upper respiratory tract infection, nasopharyngitis, headache, there were no significant differences between Ustekinumab and placebo, the two groups of Ustekinumab had no significant differences too. Conclusion The present study shows Ustekinumab to be safe and effective for patients with moderate-severe plaque psoriasis.
  • [1]
    赵辨. 中国临床皮肤病学[M]. 江苏科学技术出版社, 2009: 1008-1010.
    [2]
    Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis[J].N Engl J Med, 2007,356(6): 580-592.
    [3]
    Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)[J]. Lancet, 2008,371(9625): 1665-1674.
    [4]
    Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of Ustekinumab, a human interleukin-12/23 monoclonal antibody,in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)[J]. Lancet, 2008,371(9625): 1675-1684.
    [5]
    Tsai T, Ho J, Song M, et al. Efficacy and safety of Ustekinumab for the treatment of moderate-to-severe psoriasis: A phase Ⅲ, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)[J]. J Dermatol Sci,2011,63 (3): 154-163.
    [6]
    Product monograph. Stelara (Ustekinumab) [EB/OL]. Toronto, Ontario: Centocor Ortho Biotech Inc, December 2009.

Catalog

    Article views (178) PDF downloads (604) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return